XML 33 R20.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting

Note 10. Segment Reporting

The Company currently operates and manages its business as one reportable segment, to develop therapies to protect transplanted organs and prevent rejection. The Company's chief operating decision maker (the “CODM”), is the chief executive officer. The financial results of the Company's operations are managed and reported to the CODM. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions.

As a single reportable segment entity, the CODM assesses performance and allocates resources based on the Company's consolidated statements of operations. Significant segment expenses, as provided to the CODM, are presented as the following:

 

 

 

Year Ended
December 31,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

Tegoprubart - kidney transplantation programs

 

$

27,452

 

 

$

11,940

 

Tegoprubart - other development programs

 

 

306

 

 

 

3,186

 

Manufacturing

 

 

12,448

 

 

 

8,048

 

Personnel-related

 

 

10,706

 

 

 

8,351

 

Stock-based compensation

 

 

13,122

 

 

 

6,545

 

General and administrative expense

 

 

6,543

 

 

 

4,930

 

Total operating expenses

 

 

70,577

 

 

 

43,000

 

Loss from operations

 

 

(70,577

)

 

 

(43,000

)

Other income, net

 

 

3,924

 

 

 

2,674

 

Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds

 

 

30,900

 

 

 

(76,211

)

Provision for income taxes

 

 

(431

)

 

 

—

 

Segment and net loss

 

$

(36,184

)

 

$

(116,537

)